Phase 1/2RecruitingNCT05696366
Sotagliflozin plus volagidemab adjunct combination
UCSD crossover trial testing combined SGLT1/2 inhibition and glucagon-receptor antagonism to address glycemia, ketogenesis, insulin resistance and diabetes burden in T1D.
Primary endpoints
- Change in HbA1c
Results so far
No results posted yet.